Prioritization canceled: vaccine from Johnson & Johnson in Germany in the future probably primarily for people over 60 | message
Shares in this article
After medical information, however, younger people can also decide, the federal and state health ministers decided, as the German press agency learned on Monday. The prioritization for this vaccine is canceled in medical practices and company doctors at the same time. This will be done from this Monday. Federal Health Minister Jens Spahn (CDU) wanted to explain the procedure in Berlin in the morning.
As stated in the resolution of the Conference of Health Ministers, ministers take “the reported cases of cerebral vein thrombosis in connection with vaccination with the Johnson & Johnson vaccine” seriously. Similar to the AstraZeneca vaccine, such serious side effects were very rare.
Against this background, the Standing Vaccination Commission proposed the recommendation to vaccinate the preparation “for people aged> 60”. As with vaccinations with the AstraZeneca vaccine, vaccination should also be possible for under-60s after medical information and an individual risk analysis. The special thing about the vaccine from Johnson & Johnson is that, unlike the corona vaccines used so far, only one syringe is sufficient for full protection.
Just last week, the health ministers decided that corona vaccinations with the AstraZeneca preparation will be possible for everyone in the future, if those willing to vaccinate decide with their doctor. The prioritization with a fixed priority list for this vaccine has already been completely canceled.
Of the 34.4 million vaccine doses administered so far, only around 18,000 have come from Johnson & Johnson. Deliveries should now increase. By the weekend, 7.6 million or 9.1 percent of all German citizens had been fully vaccinated. Soon every third person has had at least one first injection: 32.3 percent.
Spahn: Ten million cans of Johnson & Johnson by the end of July
After the first deliveries of the corona vaccine by the US company Johnson & Johnson in Germany, Federal Minister of Health Jens Spahn (CDU) expects ten million vaccine doses by the end of July. That was what Spahn said on Monday in Berlin. The vaccine will generally be used in Germany in the future for people aged 60 and over, as Spahn confirmed. However, after medical advice, younger people can also opt for it. The federal and state health ministers decided that morning.
The prioritization for this vaccine is canceled in medical practices and company doctors at the same time. As with the AstraZeneca vaccine, very rare cases of thrombosis as side effects are the reason for the restriction for younger people.
Spahn explained that significantly more than 60 percent of the over-60s were vaccinated, in some federal states over 70 percent. By the end of May, all people over 60 in this age group who want to be vaccinated should be vaccinated. Most of the Johnson & Johnson vaccine comes afterwards.
Therefore, for a pragmatic further approach to the vaccination campaign, “we should give up prioritization for the vaccine from Johnson & Johnson, as with AstraZeneca”. After medical advice and an individual decision, all younger people could be vaccinated with it.
Norwegian experts on Johnson & Johnson vaccine waiver
A committee of experts from the Norwegian government and the country’s leading health agency recommend not to use AstraZeneca and Johnson & Johnson’s corona vaccines. In a report presented on Monday, the committee came to the conclusion, after further investigation, that the two funds should not be taken into account in the ongoing vaccination campaign. However, he recommended that the vaccines be made available outside of the campaign. The committee was divided on the conditions for this.
Health Minister Bent Høie said he would now carefully examine the report and use it as a basis for a decision on the use of the two vaccines, along with a recommendation from the FHI Health Institute. His government underlined that the committee viewed the funds as an aggregate as effective vaccines against Covid-19. The recommendation not to use them in the current campaign is based, among other things, on the current infection situation in Norway – which is currently quite good compared to other countries.
The Norwegian government asked the committee about four weeks ago to give its assessment of the use of the two vaccines by May 10. Even then, the FHI had recommended that the AstraZeneca preparation should be completely removed from the vaccination campaign because of the risk of rare, serious side effects. Norway had stopped the use of AstraZeneca on March 11 as a precautionary measure after rare blood clots occurred after the vaccination, including deaths. Johnson & Johnson has not yet been administered.
So far, around one and a half million people in Norway have received their first corona vaccination, and around half a million their second. The majority of them received the vaccine from BioNTech / Pfizer. Almost 5.4 million people live in Norway.
/ bw / ctt / DP / jha
More news about Johnson & Johnson
Image Sources: Gil C / Shutterstock.com